Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
← catalyst calendarNCT06822790 · readout ≤ 712 d
Sponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
869estimated
Sites
255
Countries
Argentina, Australia, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-09 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertriglyceridemia
Intervention
- Drug: Plozasiran Injection — also filed as ARO-APOC3
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Events (TEAEs)
measured From first dose of study drug through Month 24
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed